A recent study performed by AstraZeneca and MedImmue reveals, provisionally, that a Phase III trial with the drug Imfinzi, also known as durvalumab, gives longer life to patients with advanced, inoperable, non-small cell lung cancer (NSCLC). The trial, known as PACIFIC Phase 3, tests Imfinzi in comparison to placebo drugs in patients […]
Continue reading